All In Biotech

Drug Trial Radar · NCT05346224

A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Pertuzumab Biosimilar HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Apr 25, 2022

Primary completion

May 15, 2024

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Shanghai Henlius BiotechIndustry
Sponsor type
Industry
First posted
Apr 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase III, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of pertuzumab biosimilar HLX11 vs. EU-Perjeta® on HER2-positive and HR-negative early-stage or locally advanced breast cancer with a primary tumor \> 2 cm. Patients are random assignment to 2 arms and treatment with either HLX11 or EU-Perjeta® , and received neoadjuvant THP regimen every 3- weeks 4 cycles,adjuvant AC every 3- weeks 4 cycles and pertuzumab+trastuzumab(HP) every 3- weeks 13cycles.

Conditions

  • Breast Cancer
  • Breast Neoplasms
  • HER2-positive Breast Cancer

Interventions

  • HLX11Drug

    Neoadjuvant(q3w/cycle,total 4cycle): HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11(loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle

  • EU-Perjeta®Drug

    Neoadjuvant(q3w/cycle,total 4cycle): Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w)+trastuzumab(loading dose of 8 mg/kg IV, followed by 6mg/kg IV q3w)+docetaxel(75mg/m2 IV q3w) Adjuvant: doxorubicin( 60 mg/m2 IV q3w)+cyclophosphamide( 600 mg/m2 IV q3w),total 4 cycle; trastuzumab(loading dose of 8mg/m2 IV , followed by 6 mg/m2 IV q3w)+HLX11 or Perjeta (loading dose of 840 mg IV , followed by 420 mg IV q3w), 13cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The total pathological complete response (tpCR) rate assessed by the Independent Review Committee (IRC)Time frame: immediately after the surgery

Locations

79 sites in 4 countries. Site status is shown where the registry gives one.

  • the First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The first affiliated hospital of Anhui Medical University

    Hefei, Anhui, China

  • The first affiliated hospital of USTC (Anhui Provincial Hospital)

    Hefei, Anhui, China

  • Lu'an people's hospital of Anhui ProvinceLuan

    Lu'an, Anhui, China

  • Maanshan People's Hospital

    Ma’anshan, Anhui, China

  • Yijishan Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • he First Affiliated Hospital of Chongqing Medical University

    Chongqi, Chongqing Municipality, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Affiliated Cancer Hospital and Institute of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Sun Yat-Sun Yat-sen Hospital affiliated to Sun Yat-sen Universitysen Hospital affiliated to Sun Yat-sen University

    Guanzhou, Guangdong, China

  • Jieyang People's Hospital

    Jieyang, Guangdong, China

  • Meizhou People's Hospital

    Meizhou, Guangdong, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Shantou Central Hospital

    Shantou, Guangdong, China

  • Yue Bei People's Hospital

    Shaoguan, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Zhongshan People's Hospital

    Zhongshan, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China

  • Affiliated Tumor Hospital of Guizhou Medical University

    Guiyang, Guzhou, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • Tangshan People's Hospital

    Tangshan, Hebei, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • The First Affiliated Hospital of Henan University of science and Technology

    Luoyang, Henan, China

  • Nanyang Central Hospital

    Nanyang, Henan, China

  • The First Affiliated Hospital of the Xinxiang Medical University

    Xinxiang, Henan, China

  • Xinxiang Central Hospital

    Xinxiang, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The Third Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Union Hospital, Tongji Medical College,Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Xiangya Hospital Of Central South University

    Changsha, Hunan, China

Showing 40 of 79 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.